MALARIA DRUG CUT COVID-19 DEATHS

HYDROXYCHLOROQUINE  STUDY:

The International Journal Of Infectious Diseases found that the use of Hydroxycholoroquine, A drug used to treat Malaria,  plus Azithromycin was associated with a 66% reduction in the risk of death as compared to controls; the analysis also suggested a larger effectiveness of Hydroxychloroquine with less severe Covid-19 disease. Results are remarkably similar to Arshed and the Henry Ford Health study.

Deaths After Early Use

Objective: The purpose of this study was to evaluate the role of hydroxychloroquine therapy alone and in combination with azithromycin in hospitalized patients positive for COVID-19.
Design: Multi-center retrospective observational study.
Setting: The Henry Ford Health System (HFHS) in Southeast Michigan: large six hospital integrated health system; thelargest of hospitals is an 802-bedquaternary academic teachinghospitalin urban Detroit,Michigan.
Participants: Consecutive patients hospitalized with a COVID-related admission in the health system from March 10, 2020 to May 2, 2020 were included. Only the first admission was included for patients with multiple admissions. All patients evaluated were 18 years of age and older and were treated as inpatients for at least 48 h unless expired within 24 h.
Exposure: Receipt of hydroxychloroquine alone, hydroxychloroquine in combination with azithromycin, azithromycin alone, or neither.
Main outcome: The primary outcome was in-hospital mortality.
Results: Of 2,541 patients, with a median total hospitalization time of 6 days (IQR: 4–10 days), median age was 64 years (IQR:53–76 years), 51% male, 56% African American, with median time to follow-up of 28.5 days (IQR:3–53). Overall in-hospital mortality was 18.1% (95% CI:16.6%–19.7%); by treatment:
hydroxychloroquine + azithromycin, 157/783 (20.1% [95% CI: 17.3%–23.0%]), hydroxychloroquine alone, 162/1202 (13.5% [95% CI: 11.6%–15.5%]), azithromycin alone, 33/147 (22.4% [95% CI: 16.0%–30.1%]), and neither drug, 108/409 (26.4% [95% CI: 22.2%–31.0%]). Primary cause of mortality was respiratory failure
(88%); no patient had documented torsades de pointes. From Cox regression modeling, predictors of mortality were age>65 years (HR:2.6 [95% CI:1.9–3.3]), white race (HR:1.7 [95% CI:1.4–2.1]), CKD (HR:1.7 [95%CI:1.4–2.1]), reduced O2 saturation level on admission (HR:1.5 [95%CI:1.1–2.1]), and ventilator use during admission (HR: 2.2 [95%CI:1.4–3.3]).

Hydroxychloroquine provided a 66% hazard ratio reduction, and hydroxychloroquine + azithromycin 71% compared to neither treatment (p<0.001).

Conclusions and relevance: In this multi-hospital assessment, when controlling for COVID-19 risk factors, treatment with hydroxychloroquine alone and in combination with azithromycin was associated with reduction in COVID-19 associated mortality. Prospective trials are needed to examine this impact.
© 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-ncnd/4.0/).
* Corresponding author at: Division of Infectious Diseases, Henry Ford Hospital, Detroit, MI 48202, United States.

2 Comments

  1. Nance says:

    Until we find a vaccine we will never be able to eradicate this Virus. That is why lock down policies have never worked. 99% of infections are mild, with many of the healthy not knowing they have it. What we have to do is protect the vulnerable and that means isolating the aged and those with pre-existing health conditions. After the Lockdown is over, when the infection numbers are reduced, it will flare up again in possibly an even a more virulent form and meanwhile our economy is being flattened.

  2. Anonyme says:

    According to LANCET.
    “In our analysis full lock downs and widespread Covid-19 testing were not associated with reductions in the number of critical cases or overall mortality”.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

*

*